About FibroGen
FibroGen is a company based in San Francisco (United States) founded in 1993 by Rory Riggs. FibroGen has raised $215.5 million across 8 funding rounds from investors including Goldman Sachs, T. Rowe Price and Janus Henderson Investors. The company has 225 employees as of December 31, 2024. FibroGen offers products and services including Roxadustat and FG-3246. FibroGen operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter San Francisco, United States
- Employees 225 as on 31 Dec, 2024
- Founders Rory Riggs
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Fibrogen, Inc
-
Annual Revenue
$29.62 M (USD)-36.71as on Dec 31, 2024
-
Net Profit
-$47.58 M (USD)83.26as on Dec 31, 2024
-
EBITDA
-$128.27 M (USD)57.27as on Dec 31, 2024
-
Total Equity Funding
$215.5 M (USD)
in 8 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Dec 08, 2014
-
Investors
Goldman Sachs
& 14 more
-
Employee Count
225
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of FibroGen
FibroGen is a publicly listed company on the NASDAQ with ticker symbol FGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of FibroGen
FibroGen offers a comprehensive portfolio of products and services, including Roxadustat and FG-3246.
Drug for treating anemia associated with chronic kidney disease
Therapy targeting prostate cancer through targeted mechanisms
People of FibroGen
Unlock access to complete
Leadership Team
13 people
Software Development Team
11 people
Product Management Team
8 people
Legal and Compliance
4 people
Finance and Accounting
4 people
Human Resources and Administration
4 people
Operations Team
3 people
Associate Team
3 people
Unlock access to complete
Funding Insights of FibroGen
FibroGen has successfully raised a total of $215.5M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in FibroGen
FibroGen has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, T. Rowe Price and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Biotechnology investments are targeted by the venture capital firm.
|
Locked | Locked | Locked | |
|
Early-stage life sciences startups are funded by Bio Fund Management.
|
Locked | Locked | Locked |
Investor details for FibroGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by FibroGen
Investment portfolio details for FibroGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - FibroGen
Detailed financials for FibroGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fibrogen Comparisons
Peer comparison for FibroGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of FibroGen
FibroGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of FibroGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fibrogen
Complete news archive for FibroGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about FibroGen
FibroGen was founded in 1993 and raised its 1st funding round 9 years after it was founded.
FibroGen is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
FibroGen is a funded company, having raised a total of $215.5M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at FibroGen is 225.
Annual revenue of FibroGen is $29.62M as on Dec 31, 2024.
FibroGen was founded in 1993 and is headquartered in San Francisco, United States, within the biotechnology sector. Clinical programs in anemia, fibrosis, and oncology have been established through research on connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. FG-4592, an oral HIF prolyl hydroxylase inhibitor, is advanced for anemia associated with chronic kidney disease. FG-3019, a monoclonal antibody, targets idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis.
FibroGen's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
FibroGen offers Roxadustat and FG-3246.
Yes, FibroGen is publicly traded on NASDAQ under the ticker symbol FGEN.
FibroGen has 15 investors. Key investors include Goldman Sachs, T. Rowe Price, Janus Henderson Investors, Sigma Capital Group, and Oz Management.
The ticker symbol of FibroGen is FGEN on NASDAQ.